文献速递认知障碍与痴呆帕金森病与运动障碍

帕金森病老年患者痴呆治疗模式及明显处方错误

Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease.
PubMed 文献 · JAMA Neurol · 2019-01-01

该横断面分析纳入2014年美国268407例65岁及以上帕金森病医保受益人,27.2%被处方至少1种抗痴呆药;在64017例接受乙酰胆碱酯酶抑制剂(ACHEI)者中,44.5%至少发生1次高效价抗胆碱能药与ACHEI同时暴露的明显处方错误,且存在地区聚集。

要点

  • 268407例帕金森病医保受益人中73093例(27.2%)被处方至少1种抗痴呆药。
  • 64017例接受ACHEI者中28495例(44.5%)至少发生1次高效价抗胆碱能药与ACHEI同时暴露。
  • 该处方错误在美国南部和中西部各州呈高 prevalence 聚集(Moran I=0.24;P<.001)。

核心结论

  • 帕金森病患者的痴呆用药因种族/族裔和性别而异;在接受认知障碍治疗者中,潜在不适当处方常见,并因种族/族裔、性别和地理位置而异;这些发现可作为改善帕金森病患者照护质量与结局的国家和地方靶点。

研究设计与样本

  • 该研究为横断面分析,纳入2014年1月1日至2014年12月31日连续12个月具有住院、门诊和处方药覆盖的65岁及以上帕金森病成人Medicare受益人,排除其他帕金森综合征患者。
  • 数据提取自2014年Centers for Medicare & Medicaid Services的Carrier、Beneficiary Summary和Prescription Drug Event研究可识别文件;数据分析于2017年8月1日至2017年11月30日进行。
  • 共纳入268407例受益人(平均[SD]年龄78.9[7.5]岁;男性134575例[50.1%])。

主要发现

  • 268407例受益人中有73093例(27.2%)被处方至少1种抗痴呆药;最常用为多奈哌齐盐酸盐(46027例使用者[63.0%]),其次为美金刚盐酸盐(30578例[41.8%)和利斯的明酒石酸盐(19278例[26.4%])。
  • 黑人(AOR 1.33;95%CI 1.28-1.38)和西班牙裔(AOR 1.28;95%CI 1.22-1.35)受益人更可能被处方痴呆药,美洲原住民受益人更不可能(AOR 0.62;95%CI 0.51-0.74);女性较男性更不可能被处方痴呆药(AOR 0.85;95%CI 0.84-0.87)。
  • 64017例接受ACHEI的受益人中有28495例(44.5%)至少发生1次高效价抗胆碱能药-ACHEI事件;西班牙裔(AOR 1.11;95%CI 1.00-1.23)和女性(AOR 1.30;95%CI 1.25-1.35)受益人发生该never event的比值更高。
  • 该处方错误患病率在美国呈统计学显著聚集(Moran I=0.24;P<.001),高患病率聚集位于南部和中西部各州。

关键数值与推荐

  • 痴呆药处方率:268407例中73093例(27.2%)。
  • 高效价抗胆碱能药与ACHEI同时暴露:64017例接受ACHEI者中28495例(44.5%)。
  • 空间聚集:Moran I=0.24;P<.001。

临床怎么用

  • 作者认为这些发现可作为改善帕金森病患者照护质量与结局的国家和地方靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Dementia is common in Parkinson disease, but few data exist on dementia treatment patterns or the concurrent use of acetylcholinesterase inhibitors (ACHEIs) and anticholinergic medications, a frank prescribing error. OBJECTIVES: To describe dementia treatment patterns, and to determine the extent to which the concurrent use of ACHEIs and drugs with strong anticholinergic activity occurs among individuals with Parkinson disease in the United States. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional analysis included adult Medicare beneficiaries (aged 65 years or older) with Parkinson disease diagnosis with 12 consecutive months of inpatient, outpatient, and prescription drug coverage from January 1, 2014, through December 31, 2014. Beneficiaries with other parkinsonian syndromes were excluded. Demographic, geographic, prescription claims, and other data were extracted from the 2014 Carrier, Beneficiary Summary, and Prescription Drug Event research identifiable files of the Centers for Medicare & Medicaid Services. Data analysis was conducted from August 1, 2017, to November 30, 2017. MAIN OUTCOMES AND MEASURES: Primary outcomes were use of dementia drug, specific dementia medication, and concurrent exposure to a high-potency anticholinergic drug and an ACHEI. Descriptive analyses and multivariable logistic regression models determined the extent to which patient characteristics and comorbid conditions were associated with dementia treatment or with a high-potency anticholinergic and ACHEI never event. RESULTS: Of 268 407 Medicare beneficiaries with Parkinson disease (mean [SD] age, 78.9 [7.5]; 134 575 male [50.1%]), most were identified in the files as white (232 831 [86.7%]), followed by black (14 629 [5.5%]), Hispanic (7176 [2.7%]), Asian (7115 [2.7%]), and Native American (874 [0.3%]). Among these beneficiaries, 73 093 (27.2%) were given a prescription for at least 1 antidementia medication. The most commonly prescribed medication was donepezil hydrochloride (46 027 [63.0%] users), followed by memantine hydrochloride (30 578 [41.8%] users) and rivastigmine tartrate (19 278 [26.4%] users). Dementia drugs were more likely to be prescribed to black (adjusted odds ratio [AOR], 1.33; 95% CI, 1.28-1.38) and Hispanic (AOR, 1.28; 95% CI, 1.22-1.35) beneficiaries and less likely for Native American beneficiaries (AOR, 0.62; 95% CI, 0.51-0.74). Women were less likely than men to be given a prescription for dementia medication (AOR, 0.85; 95% CI, 0.84-0.87). Of the 64 017 beneficiaries receiving an ACHEI, 28 495 (44.5%) experienced at least 1 high-potency anticholinergic-ACHEI event. Hispanic (AOR, 1.11; 95% CI, 1.00-1.23) and women (AOR, 1.30; 95% CI, 1.25-1.35) beneficiaries had greater odds of experiencing this never event. Statistically significant clusters of the prevalence of this prescribing error were observed across the United States (Moran I = 0.24; P < .001), with clusters of high prevalence in the southern and midwestern states. CONCLUSIONS AND RELEVANCE: Dementia medication use by persons with Parkinson disease varies by race/ethnicity and sex; potentially inappropriate prescribing is common among those being treated for cognitive impairment and varies by race/ethnicity, sex, and geography. These findings may serve as national and local targets for improving care quality and outcomes for persons with Parkinson disease.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Mantri S, Fullard M, Gray SL, et al. Patterns of Dementia Treatment and Frank Prescribing Errors in Older Adults With Parkinson Disease. JAMA Neurol. 2019. PMID: 30285047. doi:10.1001/jamaneurol.2018.2820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。